Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors

Allison M. Quick, Filadelfiya Zvinovski, Catherine Hudson, Andrew Hundley, Cynthia Evans, Anupama Suresh, Julie A. Stephens, Elizabeth Arthur, Bhuvaneswari Ramaswamy, Raquel E. Reinbolt, Anne M. Noonan, Jeffrey Bryan VanDeusen, Robert Wesolowski, Daniel G. Stover, Nicole Olivia Williams, Sagar D. Sardesai, Karen L. Smith, Stephanie S. Faubion, Charles L. Loprinzi, Maryam B. Lustberg

Research output: Contribution to journalArticle

Abstract

Purpose: Fractional CO2 laser therapy is an emerging treatment for genitourinary syndrome of menopause (GSM). The objective of this study was to determine the feasibility and preliminary efficacy of fractional CO2 laser therapy in breast cancer survivors. Methods: This was a single arm feasibility study of breast cancer survivors with dyspareunia and/or vaginal dryness. Participants received three treatments of fractional CO2 laser therapy at 30-day intervals and returned for a 1-month follow-up. Feasibility was defined as treatment completion without serious adverse events (SAE) in 80% of patients. We collected data on the Vaginal Assessment Scale (VAS), the Female Sexual Function Index (FSFI), the Urinary Distress Index (UDI), and SAE. Results: A total of 64 patients participated in the study. The majority of women had Estrogen receptor/Progesterone receptor (ER/PR) positive/Her2neu negative (n = 37; 63%), stage I (n = 32, 54%) or II (n = 19, 32%) breast cancer. Most were receiving endocrine therapy (n = 54, 92%), most commonly aromatase inhibitors (AI; n = 40, 68%). Fifty-nine (88.1%) of those enrolled completed all treatments according to protocol with no reported SAE. No patient withdrew due to SAE. The scores of the VAS (mean Δ − 0.99; 95% CI [− 1.19, − 0.79], p < 0.001)), FSFI (mean Δ 9.67; 95% CI [7.27, 12.1], p < 0.001), and UDI (mean Δ − 8.85; 95% CI [− 12.75, − 4.75], p < 0.001)) improved from baseline to follow-up. Conclusion: Fractional CO2 laser treatment for breast cancer survivors is feasible and appears to reduce GSM symptoms across treatment and follow-up.

Original languageEnglish (US)
JournalSupportive Care in Cancer
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Gas Lasers
Laser Therapy
Menopause
Survivors
Breast Neoplasms
Therapeutics
Dyspareunia
Aromatase Inhibitors
Feasibility Studies
Estrogen Receptors

Keywords

  • Breast cancer
  • Fractional CO2 laser therapy
  • Genitourinary syndrome of menopause
  • Vaginal atrophy

ASJC Scopus subject areas

  • Oncology

Cite this

Quick, A. M., Zvinovski, F., Hudson, C., Hundley, A., Evans, C., Suresh, A., ... Lustberg, M. B. (Accepted/In press). Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors. Supportive Care in Cancer. https://doi.org/10.1007/s00520-019-05211-3

Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors. / Quick, Allison M.; Zvinovski, Filadelfiya; Hudson, Catherine; Hundley, Andrew; Evans, Cynthia; Suresh, Anupama; Stephens, Julie A.; Arthur, Elizabeth; Ramaswamy, Bhuvaneswari; Reinbolt, Raquel E.; Noonan, Anne M.; VanDeusen, Jeffrey Bryan; Wesolowski, Robert; Stover, Daniel G.; Williams, Nicole Olivia; Sardesai, Sagar D.; Smith, Karen L.; Faubion, Stephanie S.; Loprinzi, Charles L.; Lustberg, Maryam B.

In: Supportive Care in Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Quick, AM, Zvinovski, F, Hudson, C, Hundley, A, Evans, C, Suresh, A, Stephens, JA, Arthur, E, Ramaswamy, B, Reinbolt, RE, Noonan, AM, VanDeusen, JB, Wesolowski, R, Stover, DG, Williams, NO, Sardesai, SD, Smith, KL, Faubion, SS, Loprinzi, CL & Lustberg, MB 2019, 'Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors', Supportive Care in Cancer. https://doi.org/10.1007/s00520-019-05211-3
Quick, Allison M. ; Zvinovski, Filadelfiya ; Hudson, Catherine ; Hundley, Andrew ; Evans, Cynthia ; Suresh, Anupama ; Stephens, Julie A. ; Arthur, Elizabeth ; Ramaswamy, Bhuvaneswari ; Reinbolt, Raquel E. ; Noonan, Anne M. ; VanDeusen, Jeffrey Bryan ; Wesolowski, Robert ; Stover, Daniel G. ; Williams, Nicole Olivia ; Sardesai, Sagar D. ; Smith, Karen L. ; Faubion, Stephanie S. ; Loprinzi, Charles L. ; Lustberg, Maryam B. / Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors. In: Supportive Care in Cancer. 2019.
@article{18398d6a3c4942eab481dc96f607f6ef,
title = "Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors",
abstract = "Purpose: Fractional CO2 laser therapy is an emerging treatment for genitourinary syndrome of menopause (GSM). The objective of this study was to determine the feasibility and preliminary efficacy of fractional CO2 laser therapy in breast cancer survivors. Methods: This was a single arm feasibility study of breast cancer survivors with dyspareunia and/or vaginal dryness. Participants received three treatments of fractional CO2 laser therapy at 30-day intervals and returned for a 1-month follow-up. Feasibility was defined as treatment completion without serious adverse events (SAE) in 80{\%} of patients. We collected data on the Vaginal Assessment Scale (VAS), the Female Sexual Function Index (FSFI), the Urinary Distress Index (UDI), and SAE. Results: A total of 64 patients participated in the study. The majority of women had Estrogen receptor/Progesterone receptor (ER/PR) positive/Her2neu negative (n = 37; 63{\%}), stage I (n = 32, 54{\%}) or II (n = 19, 32{\%}) breast cancer. Most were receiving endocrine therapy (n = 54, 92{\%}), most commonly aromatase inhibitors (AI; n = 40, 68{\%}). Fifty-nine (88.1{\%}) of those enrolled completed all treatments according to protocol with no reported SAE. No patient withdrew due to SAE. The scores of the VAS (mean Δ − 0.99; 95{\%} CI [− 1.19, − 0.79], p < 0.001)), FSFI (mean Δ 9.67; 95{\%} CI [7.27, 12.1], p < 0.001), and UDI (mean Δ − 8.85; 95{\%} CI [− 12.75, − 4.75], p < 0.001)) improved from baseline to follow-up. Conclusion: Fractional CO2 laser treatment for breast cancer survivors is feasible and appears to reduce GSM symptoms across treatment and follow-up.",
keywords = "Breast cancer, Fractional CO2 laser therapy, Genitourinary syndrome of menopause, Vaginal atrophy",
author = "Quick, {Allison M.} and Filadelfiya Zvinovski and Catherine Hudson and Andrew Hundley and Cynthia Evans and Anupama Suresh and Stephens, {Julie A.} and Elizabeth Arthur and Bhuvaneswari Ramaswamy and Reinbolt, {Raquel E.} and Noonan, {Anne M.} and VanDeusen, {Jeffrey Bryan} and Robert Wesolowski and Stover, {Daniel G.} and Williams, {Nicole Olivia} and Sardesai, {Sagar D.} and Smith, {Karen L.} and Faubion, {Stephanie S.} and Loprinzi, {Charles L.} and Lustberg, {Maryam B.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00520-019-05211-3",
language = "English (US)",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors

AU - Quick, Allison M.

AU - Zvinovski, Filadelfiya

AU - Hudson, Catherine

AU - Hundley, Andrew

AU - Evans, Cynthia

AU - Suresh, Anupama

AU - Stephens, Julie A.

AU - Arthur, Elizabeth

AU - Ramaswamy, Bhuvaneswari

AU - Reinbolt, Raquel E.

AU - Noonan, Anne M.

AU - VanDeusen, Jeffrey Bryan

AU - Wesolowski, Robert

AU - Stover, Daniel G.

AU - Williams, Nicole Olivia

AU - Sardesai, Sagar D.

AU - Smith, Karen L.

AU - Faubion, Stephanie S.

AU - Loprinzi, Charles L.

AU - Lustberg, Maryam B.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: Fractional CO2 laser therapy is an emerging treatment for genitourinary syndrome of menopause (GSM). The objective of this study was to determine the feasibility and preliminary efficacy of fractional CO2 laser therapy in breast cancer survivors. Methods: This was a single arm feasibility study of breast cancer survivors with dyspareunia and/or vaginal dryness. Participants received three treatments of fractional CO2 laser therapy at 30-day intervals and returned for a 1-month follow-up. Feasibility was defined as treatment completion without serious adverse events (SAE) in 80% of patients. We collected data on the Vaginal Assessment Scale (VAS), the Female Sexual Function Index (FSFI), the Urinary Distress Index (UDI), and SAE. Results: A total of 64 patients participated in the study. The majority of women had Estrogen receptor/Progesterone receptor (ER/PR) positive/Her2neu negative (n = 37; 63%), stage I (n = 32, 54%) or II (n = 19, 32%) breast cancer. Most were receiving endocrine therapy (n = 54, 92%), most commonly aromatase inhibitors (AI; n = 40, 68%). Fifty-nine (88.1%) of those enrolled completed all treatments according to protocol with no reported SAE. No patient withdrew due to SAE. The scores of the VAS (mean Δ − 0.99; 95% CI [− 1.19, − 0.79], p < 0.001)), FSFI (mean Δ 9.67; 95% CI [7.27, 12.1], p < 0.001), and UDI (mean Δ − 8.85; 95% CI [− 12.75, − 4.75], p < 0.001)) improved from baseline to follow-up. Conclusion: Fractional CO2 laser treatment for breast cancer survivors is feasible and appears to reduce GSM symptoms across treatment and follow-up.

AB - Purpose: Fractional CO2 laser therapy is an emerging treatment for genitourinary syndrome of menopause (GSM). The objective of this study was to determine the feasibility and preliminary efficacy of fractional CO2 laser therapy in breast cancer survivors. Methods: This was a single arm feasibility study of breast cancer survivors with dyspareunia and/or vaginal dryness. Participants received three treatments of fractional CO2 laser therapy at 30-day intervals and returned for a 1-month follow-up. Feasibility was defined as treatment completion without serious adverse events (SAE) in 80% of patients. We collected data on the Vaginal Assessment Scale (VAS), the Female Sexual Function Index (FSFI), the Urinary Distress Index (UDI), and SAE. Results: A total of 64 patients participated in the study. The majority of women had Estrogen receptor/Progesterone receptor (ER/PR) positive/Her2neu negative (n = 37; 63%), stage I (n = 32, 54%) or II (n = 19, 32%) breast cancer. Most were receiving endocrine therapy (n = 54, 92%), most commonly aromatase inhibitors (AI; n = 40, 68%). Fifty-nine (88.1%) of those enrolled completed all treatments according to protocol with no reported SAE. No patient withdrew due to SAE. The scores of the VAS (mean Δ − 0.99; 95% CI [− 1.19, − 0.79], p < 0.001)), FSFI (mean Δ 9.67; 95% CI [7.27, 12.1], p < 0.001), and UDI (mean Δ − 8.85; 95% CI [− 12.75, − 4.75], p < 0.001)) improved from baseline to follow-up. Conclusion: Fractional CO2 laser treatment for breast cancer survivors is feasible and appears to reduce GSM symptoms across treatment and follow-up.

KW - Breast cancer

KW - Fractional CO2 laser therapy

KW - Genitourinary syndrome of menopause

KW - Vaginal atrophy

UR - http://www.scopus.com/inward/record.url?scp=85076298444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076298444&partnerID=8YFLogxK

U2 - 10.1007/s00520-019-05211-3

DO - 10.1007/s00520-019-05211-3

M3 - Article

C2 - 31811486

AN - SCOPUS:85076298444

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

ER -